In various cellular models, including iPSC-derived neural cells, immune cells and fibroblasts, PD-associated mutant LRRK2 G2019S increases mtDNA damage that is abrogated by either gene editing to correct the G2019S mutation or by treatment with LRRK2 kinase inhibitors (Howlett et al., 2017; Gonzalez-Hunt et al., 2020). The gene discussed is LRRK2; the disease is Parkinson disease.